FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

October 31, 2017 – The U.S. Food and Drug Administration (FDA) today granted accelerated approval to acalabrutinib for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence and Acting Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation … (leggi tutto)